San Francisco 49ers and IDEMIA Announce Strategic Partnership to Enhance Fan Experience
The San Francisco 49ers and IDEMIA announced a new multi-year partnership to promote and implement identity and security services from IDEMIA’S IdentoGO solution, the country’s preeminent identity-related service provider and exclusive provider of TSA Pre✓®, at Levi’s® Stadium. In addition to offering TSA Pre✓® enrollment opportunities at 49ers home games, IDEMIA will equip the stadium with biometric-based technology to assist in fan experience and security in the near future.
“We’re always looking for innovative ways to enhance security at Levi’s ® Stadium and IDEMIA’S IdentoGO technology complements our efforts as we strive to provide expedited entry for pre-approved customers, ” said Jim Mercurio, 49ers Vice President of stadium operations and Levi’s® Stadium general manager. “We look forward to working with IDEMIA to jointly deploy the first-ever Trusted Fan Program which we plan on implementing in stages. We are excited about the possibilities they bring toward enhancing the fan experience at Levi’s ® Stadium. ”
“At IDEMIA, we make it our mission to protect people and places with innovative and convenient solutions so that security doesn't get in the way of enjoying free time. This is what we are doing for millions of Americans already using the TSA Pre✓® program to travel safely,” said Didier Lamouche, CEO of IDEMIA, the company that provides IdentoGO services. “We are very excited to partner with such a progressive sports organization in technology to bring 49ers fans TSA Precheck and outfit Levi’s ® Stadium with cutting-edge biometric solutions to help them better serve their fans.”
Through innovative pilot programs focused on leveraging IdentoGO’s wide-ranging technology, the 49ers will test options to streamline fan entrance into Levi’s® Stadium, enhance the fan experience inside the stadium, and look at the implementation of biometrics at point of sale.
“Being located in Silicon Valley mandated that our organization have a close relationship with pioneering technology companies and IDEMIA certainly delivers on that characterization,” said Brent Schoeb, 49ers Vice President of corporate partnerships. “The launch of their TSA Precheck enrollment for 49ers fans who visit Levi’s ® Stadium is just the beginning of our work with them as we work to further enhance the guest experience at Levi’s ® Stadium.”
OT-Morpho is now IDEMIA, the global leader in trusted identities for an increasingly digital world, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment.
With close to €3bn in revenues, IDEMIA is the result of the coming together of OT (Oberthur Technologies) and Safran Identity & Security (Morpho). This new company counts 14,000 employees of more than 80 nationalities and serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
About the San Francisco 49ers
The San Francisco 49ers, owned by Denise and John York, currently play in the NFC West division and have won five Super Bowl trophies including Super Bowl XVI, XIX, XXIII, XXIV and XXIX. The franchise also has six conference championships and 19 divisional championships and was the first major league professional sports team to be based in San Francisco more than 70 years ago.
Elizabeth MARSHALL, T 978-215-2513
Roger HACKER, T 408-986-4890
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
LIVANOVA-PLC20.11.2017 09:45 | pressemeddelelse
LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million
CHUGAI-PHARMACEUTICAL20.11.2017 09:31 | pressemeddelelse
Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study
CA-SYNTERACT20.11.2017 09:02 | pressemeddelelse
Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam
FIORANO-SOFTWARE20.11.2017 09:02 | pressemeddelelse
Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance
JAPAN-CONTENT-SHOWCASE20.11.2017 04:02 | pressemeddelelse
Record Attendance at Japan Content Showcase 2017!
SHELL/BIO-BEAN20.11.2017 01:03 | pressemeddelelse
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum